ライフサイエンスコーパス: proliferative

1 ngradable, maculopathy, preproliferative, or proliferative), 99.6% (97.0%-99.9%) for proliferative re

2 ate both with systemic inflammation and poor proliferative ability of HIV-specific T cells; however,

3 The phenotype and proliferative ability of tumor antigen-specific CD8+ T c

4 wnregulating cyclin D1 expression, while the proliferative ability was restored in knockout HCC cells

5 to low-dose IL-2 and in patients have marked proliferative ability, further enhanced by stimulation w

6 ion of miR-124, leading to the metabolic and proliferative abnormalities in PAH ECs via PTPB1 and PKM

7 y adipogenic transcription factor peroxisome proliferative activated receptor gamma (PPARgamma) and C

8 osteen (Garcinia mangostana), and their anti-proliferative activities were tested in ovarian cancer c

9 ess Zfh1 and engage in Notch-Delta-dependent proliferative activity and generate lineal descendant po

10 7266 is involved in regulating cardiomyocyte proliferative activity and is likely associated with hyp

11 s evidenced by a significant decrease in the proliferative activity due to a reduced number of both r

12 CG encapsulating NPs led to an enhanced anti-proliferative activity in PCa cell lines compared to the

13 We assessed the anti-proliferative activity of itraconazole using an EOC cell

14 has been reported that BDNF strengthens the proliferative activity of neuronal precursor cells, faci

15 S17 exhibited strong anti-proliferative activity on other two gastric cancer cells

16 nd Pseudomonas aeruginosa) and in vitro anti-proliferative activity were evaluated.

17 -negative breast cancer biology include high proliferative activity, an increased immunological infil

18 cells, the d-peptide exerts a prolonged anti-proliferative activity.

19 capacity, anti-inflammatory effect and anti-proliferative activity.

20 h lethal disease, RB-deficient tumors had no proliferative advantage and exhibited downstream effects

21 IDH1 establishes a CD24(+) population with a proliferative advantage and stem-like transcriptional fe

22 to the infused CD34(+) graft, indicating the proliferative advantage of corrected FA-A hematopoietic

23 ), suggesting overexpressed FEN1 conferred a proliferative advantage to NSCLC.

24 sequent colonization of the vascular wall by proliferative adventitial cells that contribute to the r

25 The anti-proliferative agent hexamethylene bisacetamide (HMBA) be

26 roliferative ECs and a 1.35-fold increase in proliferative alpha-smooth muscle actin-positive cells i

27 Tumor burden and expression of proliferative and angiogenic markers was decreased in th

28 e cells (PASMCs) exhibit a "cancer-like" pro-proliferative and anti-apoptotic phenotype.

29 (ROS) and pioglitazone (PGZ) both have anti-proliferative and anti-inflammatory effects and induce a

30 Thus, sepsis unmasks compartment-specific proliferative and apoptotic regulation that is not prese

31 Ndfip1-deficient Treg cells are highly proliferative and are more likely to lose Foxp3 expressi

32 Second, in vitro CD4 T-cell proliferative and cytokine responses to HIV-specific and

33 T-cell proliferative and cytokine-producing capacities were ana

34 find that EDN3 induces a state that is both proliferative and differentiated.

35 from miR-184-overexpressing HLEKs were less proliferative and failed to seal linear scratch wounds.

36 mic model of heterogeneity based on evolving proliferative and functional beta-cell states.Betaeta-ce

37 The proliferative and functional heterogeneity among seeming

38 of Ptpn11 drove muscle stem cells out of the proliferative and into a resting state during muscle gro

39 yc drives the immediate transition to highly proliferative and invasive adenocarcinomas marked by hig

40 s enhances AKT/mTOR signalling and increases proliferative and invasive capacity in vitro and confers

41 ropose that antagonising miR-193a-3p in less proliferative and less angiogenic ECFC-derived cells wil

42 rger islet size and beta-cell mass, and more proliferative and less apoptotic beta-cells compared wit

43 eas the NS5A TCR activation induced extended proliferative and metabolic pathways as the HCV target c

44 stasis by preventing the expansion of highly proliferative and metabolically active Treg cells and by

45 morbidities of chronic diseases exhibit poor proliferative and migratory capabilities, which impair o

46 re-operated Ca(2+) influx channels (SOCs) in proliferative and migratory vascular smooth muscle cells

47 bility to identify melanomas that are highly proliferative and more prompted to respond to CDK4/6 inh

48 determines if cells couple or uncouple their proliferative and motility responses to ECM stiffness.

49 ors, whereas ATM regulated apoptosis in both proliferative and noncycling cells.

50 i-lymphangiogenic through VDR-dependent anti-proliferative and pro-apoptotic mechanisms.

51 and MDM2 induced a complementary set of anti-proliferative and pro-apoptotic proteins.

52 SRE-LUC) activity and mRNA expression of pro-proliferative and pro-migratory MKL1/2 target genes in V

53 Furthermore, Eed regulates the proliferative and regenerative capacity of adult urothel

54 se data suggest that the WNT pathway confers proliferative and survival advantages on cap cells via r

55 l, H3K27me3 depleted, Olig2 positive, highly proliferative, and diffusely spreading, thus recapitulat

56 the tumor edge which were more prevalent and proliferative, and displayed M2 polarization, whereas be

57 the PKM2/PKM1 ratio, the overall metabolic, proliferative, and inflammatory state of cells.

58 n vitro, adiponectin reduced apoptotic, anti-proliferative, and stress signals and restored STAT3 sig

59 netic protein receptor (BMPR) axis: the anti-proliferative arm of TGF-beta super family of receptors.

60 transduction cascades that drive a permanent proliferative arrest (cellular senescence) or regulated

61 nce of mammalian cells is characterized by a proliferative arrest in response to stress and the expre

62 The reversible state of proliferative arrest known as "cellular quiescence" play

63 tic example of polarity remodeling occurs in proliferative basal cells of mammalian epidermis whereup

64 stratified squamous epithelium comprised of proliferative basal cells that differentiate while migra

65 can convert rat and mouse MHs in vitro into proliferative bipotent cells, which we term chemically i

66 ate shuttle deregulation leads to a specific proliferative block due to the inability to maintain NAD

67 hat deliver a TLR9 agonist induce an initial proliferative burst that is followed by apoptotic death.

68 During this proliferative burst, expression of the Rag genes is tran

69 d to undergo a characteristic IL-7-dependent proliferative burst.

70 iveness, whereas younger beta-cells are more proliferative but less functional.

71 ssive checkpoint pathways to provide greater proliferative capabilities and an inflammatory phenotype

72 a valuable source for cell culture, its less proliferative capability emerges a challenge for the res

73 is associated with a massive decline of the proliferative capacities of the stem cell niche in the a

74 ction of ribosomes and a failure to maintain proliferative capacity after stimulation.

75 ficient, terminally mature NK cells retained proliferative capacity and exhibited heightened reconsti

76 AT1-deficient CD4(+) T cells maintain higher proliferative capacity and expression of effector cytoki

77 ine-mediated priming phase, and enhanced the proliferative capacity and hepatic regeneration ratio in

78 ed insulin secretion can result from reduced proliferative capacity and reduced islet function.

79 sociated with CD27 downregulation, retaining proliferative capacity and TCR sensitivity, displaying i

80 We assessed proliferative capacity and telomere length using flow-fl

81 ck-in megakaryocyte progenitors have reduced proliferative capacity and undergo increased cell death,

82 asts from R258C patients exhibited increased proliferative capacity compared with controls, consisten

83 tional cell lines decreases self-renewal and proliferative capacity in vitro and tumor initiation and

84 This restraint might be because of the poor proliferative capacity of aged donor hepatocytes or the

85 ion resulted in significant reduction in the proliferative capacity of cells.

86 possible mechanism contributing to impaired proliferative capacity of M. tuberculosis-specific CD4 T

87 The ex vivo proliferative capacity of M. tuberculosis-specific CD4 T

88 Ectopic FOXM1 rescues the proliferative capacity of MYC- or p53-mutant cells in sp

89 A more robust in vitro proliferative capacity of nCPCs, compared with aCPCs, co

90 Increased proliferative capacity of outer progenitors is further p

91 ations of mouse epidermis robustly increases proliferative capacity of p63(+) epidermal progenitor ce

92 n of B cell memory; instead, SpA reduced the proliferative capacity of PCs that entered the BM, dimin

93 Short telomeres block the proliferative capacity of stem cells, affecting their po

94 role for this orphan GPCR in regulating the proliferative capacity of the intestine.

95 LiPs in long-term culture did not lose their proliferative capacity or their hepatic differentiation

96 TCM exhibit greater plasticity and proliferative capacity than effector memory T cells (TEF

97 vascular smooth muscle cells, but given low proliferative capacity, a significant effect of the vari

98 ing aging despite heterogenous reductions in proliferative capacity, allowing aged muscle to mount a

99 in vivo The expression of Ki67, a marker of proliferative capacity, is predictive of expression of v

100 BE3A-mediated SIRT6 degradation promoted the proliferative capacity, migration potential, and invasiv

101 in IESCs, we observe significantly increased proliferative capacity.

102 stage differentiation and activation of pro-proliferative cell cycle genes.

103 eta has a differential effect on hippocampal proliferative cells by inhibiting neuronal proliferation

104 also detected in neurons, while ventricular proliferative cells do not display this epigenetic mark.

105 These highly proliferative cells express stem cell markers and retain

106 enance capacity, which in turn generates non-proliferative cells.

107 ibroblast phenotypes with distinct adhesive, proliferative, chemotactic and matrix-degrading characte

108 iate 1 risk myelodysplastic syndromes or non-proliferative chronic myelomonocytic leukaemia (white bl

109 selection of low-affinity B cell clones for proliferative clonal expansion.

110 enomic instability are maintained within the proliferative compartment.

111 f markers of non-mast cell lineages, loss of proliferative control, chromatin remodeling as well as e

112 ssue, the regeneration of which is fueled by proliferative crypt Lgr5(+) intestinal stem cells (ISCs)

113 lls from patients with HHV-8 MCD displayed a proliferative defect after stimulation with alpha-galact

114 Thus, the proliferative defect of PI3Ki-resistant cells during dru

115 cultured in the absence of PI3Ki developed a proliferative defect, increased oxygen consumption and a

116 uctions in Reln expression contribute to GCp proliferative defects and cerebellar hypoplasia in GCp-s

117 cific cell of origin that supports this high proliferative demand remains unknown.

118 Non proliferative diabetic retinopathy (NPDR) was found in 6

119 ts with no diabetic retinopathy and with non-proliferative diabetic retinopathy (NPDR).

120 ormalities in diabetic patients who have non-proliferative diabetic retinopathy (NPDR).

121 nolone acetonide (FAc) on the progression to proliferative diabetic retinopathy (PDR) and the impact

122 ine the time and risk factors for developing proliferative diabetic retinopathy (PDR) and vitreous he

123 iabetic retinopathy (NPDR) was found in 69%, proliferative diabetic retinopathy (PDR) in 31% and adva

124 ctors for events that represent worsening of proliferative diabetic retinopathy (PDR) in eyes treated

125 Proliferative diabetic retinopathy (PDR) is a common cau

126 retinal photocoagulation (PRP) when managing proliferative diabetic retinopathy (PDR), with or withou

127 inopathy (NPDR), and 2.3% for severe NPDR or proliferative diabetic retinopathy (PDR).

128 with a vitreous hemorrhage (VH) secondary to proliferative diabetic retinopathy (PDR).

129 my (PPV) for severe manifestations of active proliferative diabetic retinopathy (PDR).

130 ages of DR (diabetic macular edema [DME] and proliferative diabetic retinopathy [PDR]) have a higher

131 d with a variety of human diseases including proliferative diabetic retinopathy and wet age-related m

132 Proliferative diabetic retinopathy has been managed by p

133 Overall, the probability of progression to proliferative diabetic retinopathy or clinically signifi

134 e risk of progression from no retinopathy to proliferative diabetic retinopathy or clinically signifi

135 o determine the likelihood of progression to proliferative diabetic retinopathy or clinically signifi

136 ously untreated or post-laser treated active proliferative diabetic retinopathy were recruited from 2

137 INTERPRETATION: Patients with proliferative diabetic retinopathy who were treated with

138 cluding 0.9% of all injections that were for proliferative diabetic retinopathy), 8.3% to treat retin

139 ACCORD trial participants with no history of proliferative diabetic retinopathy.

140 permeability that are characteristic of non-proliferative diabetic retinopathy.

141 that the observed diploidization is due to a proliferative disadvantage of haploid cells compared wit

142 of Ldha, Mct1, and Mct4 as well as with more proliferative disease.

143 eutic equivalent for ASA in inflammatory and proliferative diseases without the deleterious effects o

144 mutations in DNMT3A correlate with mast cell proliferative disorders in humans, the role of DNA methy

145 ents without OSA to develop preproliferative/proliferative DR (18.4% vs. 6.1%; P = 0.02).

146 , moderate-to-severe NPDR (n = 31 [37%]), or proliferative DR (n = 21 [25%]).

147 predictor of progression to preproliferative/proliferative DR (odds ratio, 5.2; 95% CI confidence int

148 with no DR to 0.338 (0.012) in patients with proliferative DR (P < .001) and at the DVP decreased in

149 s with no DR to 1.60 (0.05) in patients with proliferative DR (P < .01) and at the DVP increased from

150 s with no DR to 1.61 (0.05) in patients with proliferative DR (P = .02).

151 61 (0.019) to 0.345 (0.020) in patients with proliferative DR (P = .04).

152 nd diabetic macular edema (DME), and 18 with proliferative DR (PDR)-and 64 age-matched nondiabetic co

153 (495 [76.2%] nonproliferative DR [NPDR], 155 proliferative DR [PDR]) were analyzed; 302 (46.5%) were

154 erage rates (proportion of participants with proliferative DR [PDR], clinically significant macular e

155 s the presence of severe nonproliferative or proliferative DR, or clinically significant macular edem

156 ssociated with reduction in preproliferative/proliferative DR.

157 ntly less likely to develop preproliferative/proliferative DR.

158 ctor for the progression to preproliferative/proliferative DR.

159 conversion of differentiated acinar cells to proliferative ductal progenitors.

160 otypes despite the fact that roots were more proliferative during early stages of development in the

161 myeloproliferation toward an exacerbated and proliferative dysplastic phenotype.

162 tric analyses revealed a twofold increase in proliferative ECs and a 1.35-fold increase in proliferat

163 The objective was to compare the anti-proliferative effect of anthocyanin-rich plant extracts

164 anslation in polysomes, and reduces the anti-proliferative effect of mTOR kinase inhibitors.

165 Individual stimuli cause proliferative effects (PHH3(+) mitotic cells, YAP transl

166 e E (GE) was found to exhibit excellent anti-proliferative effects among the tested xanthones.

167 ective inhibitor of CARM1 that exhibits anti-proliferative effects both in vitro and in vivo and, to

168 The proliferative effects of galanin were via activation of

169 g protein DNA-binding activity prevented the proliferative effects of galanin.

170 ours were particularly sensitive to the anti-proliferative effects of the agent.

171 ingle TP53 target gene required for the anti-proliferative effects of TP53 during pharmacological act

172 ZD4547 (1-5 microM) demonstrated potent anti-proliferative effects, inhibition of stemness, and suppr

173 to PL with hPL did not have significant anti-proliferative effects, suggesting that hPL is not membra

174 enewal, differentiation, and aging of highly proliferative embryonic stem cells and quiescent adult s

175 mosomal instability, observing a decrease in proliferative expression signatures.

176 e found that passengers dramatically reduced proliferative fitness ( approximately 3% per Mb), slowed

177 cancer cells and find that they have reduced proliferative fitness and stably rewired cell cycle cont

178 This mutation impaired the anti-proliferative function of caveolin-1.

179 ts were characterized by the expression of a proliferative gene expression network following infarcti

180 Indeed, while Vitamin E induced a pro-proliferative gene expression signature, Selenium alone

181 cardiomyocytes have increased expression of proliferative genes and stress response genes, such as t

182 ay, regulating Th17-induced inflammatory and proliferative genes to promote demyelinating disease.

183 ed cells types and included key effector and proliferative genes.

184 signaling pathway links the environment and proliferative germ cell accumulation.

185 The developmental accumulation of proliferative germ cells in the C. elegans hermaphrodite

186 an development and in adult post-mitotic and proliferative germ cells.

187 The GFP-labeled cells include both proliferative globose basal cells as well as immature OS

188 tissue size is a topic of intense debate as proliferative growth is homogenous.

189 inating cells, which nonautonomously promote proliferative growth of the partially transformed epithe

190 e lymphoblastic leukemia (T-ALL) is a highly proliferative hematologic malignancy that results from t

191 ories in leukocytes, representing the highly proliferative hematopoietic system, and skeletal muscle,

192 LTL represents TL in the highly proliferative hematopoietic system, whereas TL in skelet

193 e beta-cell birth, leading to functional and proliferative heterogeneity.

194 rkably neutral process involving a conserved proliferative hierarchy rooted in glioblastoma stem cell

195 population defects are a result of increased proliferative history.

196 ubpopulations distinguished by expression of proliferative, homeostatic and effector genes.

197 While TGFbeta signals are anti-proliferative in benign and well-differentiated pancreat

198 CALR(del/+) HSCs were more proliferative in vitro, but neither CALR(del/+) nor CALR

199 n adult mutants, loss of Ash1l leads to more proliferative keratinocytes in disturbed differentiation

200 Proliferative kidney disease (PKD) is a major threat to

201 We demonstrated the proliferative kinetics of BRAF-mutated melanoma cells tr

202 acterized by differences in cell morphology, proliferative kinetics, and tumor-initiating capacity.

203 at altered the equilibrium between the basal proliferative layer and suprabasal differentiating layer

204 y Lgr5(+) cells, as well as adjacent, highly proliferative Lgr5(-) cells that are able to repopulate

205 Instead, tumours are maintained by proliferative Lgr5(-) cells that continuously attempt to

206 Highly proliferative Lgr5+ stem cells maintain the intestinal e

207 of terminal end bud cells function as highly proliferative, lineage-committed MaSCs that are heteroge

208 Proliferative mammary epithelium from R-ketorolac-treate

209 Patients with highly proliferative MCL and those with TP53 mutations tend to

210 ncytotoxic T cell activation showed extended proliferative, metabolic pathways and persistence of HCV

211 s the response of CDK4/6 inhibitor in highly proliferative metastatic melanoma.

212 es switches between invasive/MITF(LO) versus proliferative/MITF(HI) states.

213 iomyocytes failed to reactivate the neonatal proliferative network following infarction, which was as

214 henotype, with the production of an aberrant proliferative neural population in surviving animals.

215 nactivation created an abnormal perivascular proliferative niche in the cerebellum that persisted in

216 eral nerves and maintains Schwann cells in a proliferative non-differentiated state, which is also as

217 alpha, via SRC family kinases, increases pro-proliferative NOTCH2 signalling in HPAH PASMCs with redu

218 ts may contribute to development of TAAD and proliferative occlusive vascular disease.

219 bsets of highly similar clonotypes, the most proliferative of which showing significant enrichment fo

220 dings suggest that 5-HT3a is indicative of a proliferative or developmental state, regardless of age,

221 ces showed equal applicability for invasive, proliferative or survival assessment of well-established

222 ll activation of both MAPK and PI3Kalpha/Akt proliferative pathways by oncogenic KRas4B-but not by HR

223 d wound closure by activating epithelial pro-proliferative pathways.

224 e anti-inflammatory effects of PY during the proliferative phase of cardiac repair by analyzing the i

225 During the proliferative phase of cutaneous wound healing, dermal f

226 T1 promoted cell senescence and reversed the proliferative phenotype observed after let-7 function wa

227 s suggest a role for NOX1 in maintaining the proliferative phenotype of some colon cancers and the po

228 upregulation functionally contributes to the proliferative phenotype of Spop knock-out prostates.

229 enescent cells, sequesters let-7 to enable a proliferative phenotype.

230 Since ECFC proliferative potential is increased in cord versus peri

231 of divisions to apoptosis, which limits the proliferative potential of a stem cell to the precise ti

232 tal phenotype of stem cells and the aberrant proliferative potential of cancer cells.

233 mechanics, leading to enhanced migratory and proliferative potential of ECs during the initiation of

234 ced tumour growth and markedly decreased the proliferative potential of lung cancer cells, leading to

235 Pf1 inactivation impairs the proliferative potential of mouse embryonic fibroblasts (

236 s mammary tumour progression by reducing the proliferative potential of tumour cells.

237 Last, PD-1+ CD4 T cells predict impaired proliferative potential yet preferentially secrete the T

238 l PRC2 activity is required to maintain DIPG proliferative potential, by repressing neuronal differen

239 ive loss of both their effector function and proliferative potential, clonal deletion, and significan

240 nd was accompanied by a profound decrease in proliferative potential.

241 f-renew and produce progenitors with limited proliferative potential.

242 undreds of hepatocyte genes and quenched the proliferative precursor program.

243 ce of phenotypic CD19(neg) plasmablasts, the proliferative precursor state to mature PCs, and demonst

244 s, and ultimately to the anti-viral and anti-proliferative properties of IFN-beta.

245 ays anti-oxidant, anti-inflammatory and anti-proliferative properties potentially beneficial in cance

246 h anti-oxidative, anti-inflammatory and anti-proliferative properties.

247 n vivo, which corroborated the in vitro anti-proliferative properties.

248 Consequently, the levels of several proliferative proteins that prevent senescence, such as

249 Its small size, high proliferative rate, embryo transparency and small amount

250 Although we found both a high CD4(+) T cell-proliferative response and TH2 cytokines production afte

251 Indeed, the proliferative response of the epithelium involves expres

252 tching or wounding, epithelia display a fast proliferative response that allows for re-establishment

253 th an antibody against CTLA4 increased their proliferative response to antigen and to CD3 stimulation

254 T cells from patients with ALF had a reduced proliferative response to antigen or CD3 stimulation com

255 l biopsies of adults and children and tested proliferative response to various gluten peptides.

256 surface phenotype, secretory mediators, and proliferative responses (referred to as an "activated st

257 sufficient help to allow optimal CD8 T cell proliferative responses to exosomal protein.

258 ity, improved lymphocyte numbers, and normal proliferative responses to mitogens.

259 ital for host-protective anti-viral and anti-proliferative responses, but signaling via this interact

260 tibody binding and induction of human T-cell proliferative responses.

261 as a therapeutic target in the treatment of proliferative retinopathies and other diseases dependent

262 vessels commonly causes vision impairment in proliferative retinopathies, including retinopathy of pr

263 is crucial for pathological angiogenesis in proliferative retinopathies.

264 This case report describes a proliferative retinopathy in a 16 year-old patient with

265 nnual dilated retinal examinations to detect proliferative retinopathy or clinically significant macu

266 lation therapy or vitrectomy, development of proliferative retinopathy, or progression of diabetic re

267 ferable retinopathy, 97.9% (94.9%-99.1%) for proliferative retinopathy.

268 but may be more extensive with sickle SC or proliferative retinopathy.

269 bfields of the deep plexus with sickle SC or proliferative retinopathy.

270 , or proliferative), 99.6% (97.0%-99.9%) for proliferative retinopathy; Retmarker 73.0% (72.0 %-74.0%

271 pon the LAM cell-metabolic reprogramming and proliferative signals that drive uncontrolled growth and

272 or combined with Vitamin E produced an anti-proliferative signature.

273 logically efficacious against deep IH in the proliferative stage, with no recurrence in patients trea

274 of reactivation of latent parasites towards proliferative stages.

275 9 was required for SJSA cells to return to a proliferative state after nutlin-3 treatment, and this e

276 nder steady-state conditions but switch to a proliferative state following hematopoietic stress, e.g.

277 a role in regulating differentiation and the proliferative state of neural progenitors through regula

278 (IL-7) availability determines the size and proliferative state of the resting T cell pool.

279 nments that induce a MITF(HI)/differentiated/proliferative state.

280 M cells only in gland bases, rather than the proliferative stem cell zone.

281 NE cells undergoing proliferative, symmetric divisions retract their basal p

282 ssociated with significant increases in both proliferative TDFSM myofibroblastic cells and TDECC chol

283 Here we show that morphogenesis is driven by proliferative terminal end buds that terminate or bifurc

284 ate the effect of HIV-Tat and cocaine on the proliferative TGF-beta signaling cascade.

285 cts that coupling clinically available, anti-proliferative therapies with ART could result in functio

286 Time to development of proliferative tissue was 9, 12, and 20 months after init

287 tic system, and skeletal muscle, a minimally proliferative tissue.

288 n most thoroughly investigated in two highly proliferative tissues prone to oncogenic transformation:

289 integrity, arrangement and morphogenesis of proliferative tissues.

290 how that beta-cells in zebrafish switch from proliferative to functional states with increasing time

291 tential in response to chemotherapy, whereas proliferative TPCs undergo apoptosis.

292 in turn, governs an exquisitely complex anti-proliferative transcriptional program that touches upon

293 longation by maintaining dividing cells in a proliferative, undifferentiated state for a longer perio

294 emolysis that promote vasomotor dysfunction, proliferative vasculopathy, and a multitude of clinical

295 OXO transcription factors in mediating these proliferative versus apoptotic fates.

296 Proliferative vitreoretinopathy (PVR) is mediated by pro

297 To profile vitreous cytokine expression of proliferative vitreoretinopathy (PVR) patients.

298 l-thickness macular hole (n = 33), recurrent proliferative vitreoretinopathy (PVR)-related retinal de

299 mes of vitreoretinal surgery for established proliferative vitreoretinopathy (PVR).

300 in pathogenesis of such retinal disorders as proliferative vitreoretinopathy and age-related macular

301 f ZIKV replication including the neocortical proliferative zone and radial columns, as well as the de